Key facts
- Eyebot’s last known valuation is $107.0M (Aug 2025).
- It has raised $28.3M; the latest was Early Stage VC ($20.0M) in Aug 2025.
- Notable investors include US National Science Foundation, General Catalyst, Village Global, AlleyCorp, MassVentures — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Eyebot
- ·The full record, as it builds
Funding rounds
No funding rounds for Eyebot are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Eyebot
Developer of an eye examination technology designed to eliminate barriers and provide quality vision care. The company offers a freestanding self-serve vision testing terminal that delivers accurate eye prescriptions directly at the point of sale via an automated experience, enabling ophthalmologists to take a proactive approach to eye care for improved quality of life and cost savings.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2021
- Employees
- 24
- Website
- eyebot.co/
- Ownership
- Privately Held (backing)
Eyebot doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Eyebot shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Eyebot in its N-PORT filings yet. We sweep new filings monthly.